Group 1 - Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is recognized as one of Billionaire Ken Fisher's 15 Most Notable Moves for 2026, indicating significant investor interest [1] - Fisher Asset Management first disclosed a stake in Arrowhead in Q2 2024, starting with approximately 12,000 shares at an average price exceeding $24, and has since increased its stake by notable percentages of 941%, 238%, 133%, and close to 25% in recent quarters [1] - Ken Fisher has expressed caution regarding investments in the biotech sector, highlighting that many companies in this field are small and not particularly profitable [1] Group 2 - Arrowhead Pharmaceuticals reported strong earnings in Q1 2026, surpassing market estimates for both earnings per share and revenue [2] - The CEO of Arrowhead highlighted key upcoming events, including the Q3 2026 readout of Phase III studies for plozasiran, which could represent a commercial opportunity valued between $3 billion and $4 billion [2] - The company's pipeline includes Plozasiran, aimed at reducing apolipoprotein C-III production, and Zodasiran, targeting angiopoietin-like protein 3, both in Phase 3 clinical trials [3]

Core Insights - Arrowhead Pharmaceuticals has transitioned into a commercial-stage organization following the FDA approval of its first medicine, REDEMPLO (plozasiran), marking a significant strategic turning point [1] - The company reported a substantial increase in revenue and net income for FQ1 2026, driven by collaborations with Novartis and Sarepta Therapeutics [4] Group 1: Company Developments - Arrowhead achieved over 100 initial prescriptions for REDEMPLO in the US and established a dedicated patient support program [2] - The company initiated a Phase 1/2a trial for ARO-DIMER-PA, the first dual-function clinical candidate targeting two genes in one molecule [2] - Arrowhead reported positive interim data from its obesity programs, particularly with ARO-INHBE showing significant weight loss when combined with tirzepatide [2] Group 2: Financial Performance - Arrowhead's revenue for FQ1 2026 reached $264 million, a significant increase compared to the previous year [4] - The company reported a net income of $30.8 million for the quarter, contrasting sharply with a loss of $173.1 million in the same period last year [4] - The revenue surge was attributed to a $200 million upfront payment from a collaboration with Novartis and a $200 million milestone payment from Sarepta Therapeutics [4] Group 3: Product Pipeline - Arrowhead's pipeline includes key products such as Plozasiran, Zodasiran, ARO-DIMER-PA, and ARO-PNPLA3, focusing on treatments for intractable diseases [5]

Arrowhead Pharmaceuticals Conference Call Summary Company Overview - **Company**: Arrowhead Pharmaceuticals (NasdaqGS:ARWR) - **Event**: 2026 Conference at the Leerink Partners Global Healthcare Conference - **Date**: March 09, 2026 Key Points Pipeline Developments - **SHASTA-3 and SHASTA-4**: Phase 3 studies for Plozasiran in the SHTG population expected to read out in Q3 2026, with last patient visit in June [11] - **Dimer/Bispecific Data**: First data from a bispecific RNA molecule targeting both PCSK9 and APOC3 for mixed hyperlipidemia patients anticipated in Q3 2026 [11] - **ARO-MAPT**: First CNS target data expected towards the end of Q3 2026, focusing on tau reduction [12] - **Obesity Targets**: Updates for ARO-ALK7 and ARO-INHBE expected in the second half of 2026, with ongoing data collection [13][14] Clinical Insights - **Inhibin E**: Early data shows promising fat redistribution and significant liver fat reduction (76.7%) in obese diabetic patients when combined with tirzepatide [18] - **ALK7**: Early indications of good knockdown in fat biopsies, with further data needed to assess its potential [20] - **Market Size**: The clinically defined FCS market may include tens of thousands of patients with triglycerides above 880 and a history of pancreatitis or abdominal pain [25] Commercial Strategy - **FCS Launch**: Rapid launch with over 100 prescriptions received, including switches from competitor Ionis [24] - **SHTG Market**: Anticipated top-line readout in Q3 2026, with plans to file a supplemental NDA (sNDA) in Q4 2026 [27] - **Pricing Strategy**: Initial focus on high-risk individuals with triglycerides above 880, estimating a target population of 750,000 to 1 million [28] Regulatory Considerations - **AP Risk**: Improvement in acute pancreatitis (AP) risk is not necessary for U.S. regulatory approval, but may be critical in Europe [30][34] - **Most-Favored-Nation Policy**: Current uncertainty may affect international pricing strategies, leading to a preference for retaining control over ex-U.S. markets [46][49] Competitive Landscape - **Innovation Focus**: Emphasis on expanding RNAi technology beyond liver diseases to various cell types, with ongoing clinical studies in multiple areas [56][66] - **Dimer Development**: The potential for synergistic effects in dimer constructs, particularly with targets like APOC3 and PCSK9, is being explored [72] Future Outlook - **Expansion Plans**: Anticipation of new cell type access every 18-24 months, with ongoing studies in CNS and pulmonary applications [66][69] - **Data Validation**: Upcoming data from ARO-MAPT and bispecifics expected to validate the platform and inform future target selections [68] Additional Insights - **Patient Convenience**: The use of prefilled syringes for FCS and auto-injectors for SHTG is expected to enhance patient adherence [40] - **Market Dynamics**: Physicians are reportedly switching to Arrowhead's products due to better activity and safety profiles compared to competitors [41] This summary encapsulates the critical developments and strategic insights from Arrowhead Pharmaceuticals' conference call, highlighting the company's focus on innovation, pipeline advancements, and market positioning.

Financial Data and Key Metrics Changes - For Q1 2026, the company reported a net income of $30.8 million, translating to an income of $0.22 per share, a significant improvement from a net loss of $173.1 million or a loss of $1.39 per share in Q1 2025 [31] - Revenue for the quarter totaled $264 million, primarily driven by licensing collaborations with Sarepta and Novartis, with approximately $229 million from the Sarepta collaboration [31][32] - Total operating expenses increased to approximately $223 million from $164 million in the prior year, driven by higher R&D and SG&A expenses [33] Business Line Data and Key Metrics Changes - The company launched its first commercial product, Redemplo, approved for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) [5][8] - Over 100 prescriptions for Redemplo have been received, with a balanced uptake across the U.S. [20] - The cardiometabolic pipeline includes ongoing studies for Zodasiran and new candidates ARO-INHBE and ARO-ALK7, with promising early results in weight loss and fat reduction [9][29] Market Data and Key Metrics Changes - The FDA approved Redemplo, marking a significant milestone for the company, with additional approvals from Health Canada and the Chinese National Medical Products Administration expected [8] - The company anticipates launching Redemplo in select EU countries and the U.K. later in 2026 [8] - The potential market for mixed hyperlipidemia, targeted by ARO-DimerPA, includes approximately 20 million people in the U.S. [11] Company Strategy and Development Direction - The company is focused on sustainable innovation and rational drug pricing, emphasizing the value offered to patients and healthcare systems [7] - Arrowhead aims to become cash flow positive and self-sustaining through multiple independent and partner launches, having completed transactions with gross proceeds of $1.33 billion [15][16] - The company is expanding its CNS portfolio with new delivery systems designed to penetrate the blood-brain barrier, targeting conditions like Alzheimer's disease [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to build on recent achievements and highlighted the potential for significant growth in 2026 and beyond [5][37] - The company expects key events in 2026, including commercial sales progress for Redemplo and readouts from phase III studies for plozasiran [37] - Management remains optimistic about the early feedback from payers and healthcare providers regarding Redemplo [21][57] Other Important Information - The company has strengthened its balance sheet significantly, with cash and investments totaling $917 million as of December 31, 2025 [34][35] - The company is not disclosing specific sales numbers for Redemplo until they become a meaningful driver of financials [32] Q&A Session Summary Question: Can you provide a breakdown of patient categories for Redemplo? - The majority of patients are from the APOC3 naive segment, with the remaining balance split roughly 50/50 between switch patients and those transitioning from the expanded access program [41][42] Question: What are the timelines for discussions with the FDA regarding obesity treatments? - Discussions with the FDA are expected around mid-year, and an IND filing is anticipated shortly thereafter [44] Question: What level of reduction in LDL-C and triglycerides are you looking for with ARO-DimerPA? - A reduction of around 40%-50% in both LDL and triglycerides would be encouraging for advancing the asset [46][47] Question: How are you thinking about potential pricing for ARO-INHBE and ARO-ALK7? - It is too early to speculate on pricing as the company is still assessing the biology and potential efficacy of these candidates [50][51] Question: Can you discuss the pancreatitis event rates in ongoing trials? - The company is not providing additional details on event rates but acknowledges that events are being observed [53][54] Question: Has the pricing for Redemplo been discussed in relation to the SHTG market? - The focus is on ensuring coverage and access for high-risk patients, with discussions reflecting the clinical and economic value of Redemplo [56][59]

Financial Data and Key Metrics Changes - The company reported a net income of $30.8 million for Q1 2026, translating to an income of $0.22 per share, a significant improvement from a net loss of $173.1 million or a loss of $1.39 per share in Q1 2025 [31] - Revenue for the quarter totaled $264 million, primarily driven by licensing collaborations with Sarepta and Novartis, with approximately $229 million from the Sarepta collaboration [31][32] - Total operating expenses increased to approximately $223 million from $164 million in the prior year, driven by higher R&D and SG&A expenses [33] Business Line Data and Key Metrics Changes - The company launched its first commercial product, Redemplo, which received FDA approval as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) [4][5] - Over 100 prescriptions for Redemplo have been received, with a balanced uptake across the U.S. and a significant proportion of patients enrolling in the patient support program [6][19] - The cardiometabolic pipeline includes ongoing studies for Zodasiran and new candidates ARO-INHBE and ARO-ALK7, with promising early data reported [9][10] Market Data and Key Metrics Changes - The company anticipates launching Redemplo in Canada and select EU countries later in 2026, with Sanofi marketing it in Greater China [8] - The U.S. market for mixed hyperlipidemia is estimated to include approximately 20 million people, representing a significant opportunity for the ARO-DimerPA candidate [11] Company Strategy and Development Direction - The company is focused on sustainable innovation and rational drug pricing, emphasizing the value of medicines to patients and healthcare systems [6] - Arrowhead aims to become cash flow positive and self-sustaining from commercial sales, with a strong emphasis on expanding its cardiometabolic and CNS portfolios [15][12] - The company has strengthened its balance sheet with $1.33 billion in gross proceeds from various transactions, enabling further development and commercialization efforts [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position to build on recent achievements and highlighted the potential for significant revenue opportunities from upcoming product launches [4][17] - The company expects key events in 2026, including commercial sales progress for Redemplo and readouts from phase III studies for plozasiran, which could represent a $3-$4 billion opportunity [38] Other Important Information - The company has received breakthrough therapy designation for plozasiran, expediting its development for severe hypertriglyceridemia [25] - Arrowhead's proprietary TRiM platform is being utilized to enhance drug delivery across various tissues, including the CNS [12] Q&A Session Summary Question: Can you provide a breakdown of patient categories for Redemplo? - The majority of patients are from the APOC3 naive segment, with the remaining balance split roughly 50/50 between switch patients and those transitioning from the expanded access program [42][43] Question: What are the expectations for the obesity programs and FDA discussions? - Discussions with the FDA are expected around mid-year, and the company does not need all data from cohorts before determining the next steps [46] Question: What level of LDL-C and triglyceride reduction is expected for ARO-DimerPA? - A reduction of around 40%-50% in LDL and triglycerides would be encouraging for advancing the asset [48][49] Question: How is pricing being considered for ARO-INHBE and ARO-ALK7? - It is too early to speculate on pricing as the company is still assessing the biology and potential efficacy of these candidates [51] Question: What are the expectations for pancreatitis event rates in ongoing trials? - The company is not providing additional details on event rates but acknowledges that events are being observed [54] Question: How is payer feedback for Redemplo shaping discussions for SHTG? - Payer discussions are focused on ensuring coverage for high-risk patients, with a strong emphasis on the clinical and economic value of Redemplo [57][60]

Investment Rating - The industry investment rating is "Outperform" [2] Core Views - The report emphasizes the continuous catalysts in the small nucleic acid industry for 2026, highlighting the potential investment opportunities within the industry chain [5][19] - The report suggests a positive outlook for innovative drugs and the industry chain, with expectations of increased global participation from domestic innovative drug companies and the introduction of more innovative projects in 2026 [11][30] - The report identifies the medical device sector as a potential area for capital inflow, with signs of improvement in leading companies and a reduction in the pressure from centralized procurement [13][34] Summary by Sections Industry Overview - The closing index for the industry is at 8657.19, with a 52-week high of 9323.49 and a low of 6876.88 [2] Recent Market Performance - The A-share pharmaceutical and biotechnology sector fell by 0.68% from January 12 to January 16, 2026, underperforming the CSI 300 index by 0.11 percentage points [9][28] - The medical research outsourcing sector performed the best among sub-sectors, rising by 3.69%, while the vaccine sector declined by 3.43% [10][28] Innovative Drugs and Industry Chain - The JPM conference highlighted the strengthening of industry development logic, with increased merger and acquisition activity among multinational corporations and breakthroughs in domestic innovative drugs [11][30] - The report recommends focusing on companies with high certainty and relatively low disruption expectations, such as Innovent Biologics and others [11][30] Medical Devices - The report notes that the medical device sector is showing signs of improvement, with leading companies reporting better performance in Q3 [13][34] - The report suggests that the pressure from centralized procurement is decreasing, which may lead to valuation recovery [13][34] Small Nucleic Acid Drugs - The report highlights several key clinical trials and data readouts expected in 2026 from companies like Alnylam, Arrowhead, and Wave Life Sciences, indicating a significant focus on the weight loss and CNS fields [6][8][27] - The report encourages attention to domestic small nucleic acid-related companies and upstream industry chains [27] Investment Recommendations - The report suggests focusing on companies in the CXO and life science services sectors, as demand for overseas R&D and production outsourcing is expected to recover steadily [12][31] - It also highlights the potential for valuation re-evaluation opportunities in the biopharmaceutical sector, particularly for blood products and vaccines [32][33]

Arrowhead Pharmaceuticals FY Conference Summary Company Overview - **Company Name**: Arrowhead Pharmaceuticals - **Ticker Symbol**: ARWR - **Market Capitalization**: Approximately $9 billion with 136 million shares outstanding [2] - **Cash and Investments**: Approximately $920 million, excluding additional funds from Sarepta and Novartis [2] Core Business and Pipeline - **Focus**: Development of RNA interference (RNAi) therapies targeting various diseases [3] - **First Commercial Launch**: Rudemplo, approved in the US, Canada, and China for lowering triglycerides in patients with familial chylomicronemia syndrome (FCS) [3] - **Pipeline**: 20 clinical stage programs, including 11 wholly owned and 9 partnered candidates [3] - **Expected Growth**: Aim to add 2-3 additional drug candidates annually [3] Key Products and Indications Rudemplo - **Indication**: Treatment of FCS, with ongoing studies for severe hypertriglyceridemia (SHTG) [7] - **Efficacy**: Achieved approximately 80% reduction in triglyceride levels in clinical studies [9] - **Market Potential**: Targeting approximately 6,500 FCS patients in the US and a broader SHTG population of about 3 million [11][12] Zodasiran - **Indication**: Treatment of homozygous familial hypercholesterolemia (HoFH) [12] - **Efficacy**: Demonstrated a 41% reduction in LDL cholesterol in HoFH patients [13] - **Market Potential**: Estimated 1,000 to 2,000 patients in the US with HoFH [13] ARO-Dimer-PA - **Indication**: Designed to treat mixed hyperlipidemia by silencing both ApoC3 and PCSK9 [15] - **Market Potential**: Approximately 20 million patients in the US with elevated LDL cholesterol and triglycerides [16] Obesity Candidates (ARO-INHBE and ARO-ALK7) - **Focus**: Targeting specific pathways to reduce visceral fat and improve metabolic outcomes [18] - **Efficacy**: ARO-INHBE showed a 9.9% reduction in visceral fat after 16 weeks [20] - **Combination Therapy**: ARO-INHBE combined with tirzepatide resulted in a 9.4% weight loss compared to 4.8% with tirzepatide alone [20] CNS Program (ARO-MAPT) - **Indication**: Targeting tau protein for Alzheimer's and tauopathies [25] - **Efficacy**: Early data shows potential for significant tau reduction in animal models [26] - **Market Potential**: Addressing a significant unmet need in neurodegenerative diseases [25] Financial Strategy and Market Position - **Pricing Strategy**: Rudemplo priced at $60,000 for both FCS and SHTG populations to ensure payer acceptance and long-term market access [36] - **Cash Management**: Strong financial position with over $900 million available to fund ongoing and future trials [47] - **Regulatory Pathways**: Potential for expedited approval based on LDL reduction for ARO-Dimer-PA [45] Upcoming Milestones - **Phase 3 Studies**: Expected readouts for SHTG in Q3 2026 and filing for SNDA in Q4 2026 [28] - **Obesity Pipeline Expansion**: Continued development of ARO-INHBE and ARO-ALK7 with additional data expected throughout 2026 [29] - **CNS Pipeline**: Initial data for ARO-MAPT anticipated in late Q3 2026 [29] Conclusion Arrowhead Pharmaceuticals is positioned to capitalize on significant market opportunities in the RNAi space, with a robust pipeline targeting high unmet medical needs across various therapeutic areas. The company’s strategic focus on pricing, cash management, and regulatory pathways aims to enhance its market presence and drive future growth.

Arrowhead Pharmaceuticals FY Conference Summary Company Overview - **Company**: Arrowhead Pharmaceuticals (NasdaqGS:ARWR) - **Event**: FY Conference held on December 03, 2025 Key Industry Insights - **Market Opportunity**: Arrowhead's first drug, Plozasiran, has been approved, targeting familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG) [3][4] - **Patient Need**: Approximately 10,000 patients with FCS require treatment to prevent severe pancreatitis, which can be fatal [4] - **Phase Three Data**: Plozasiran demonstrated an 80% reduction in triglycerides and a numerical risk reduction in pancreatitis [5] Competitive Landscape - **Pricing Strategy**: Plozasiran is priced lower than competitors like Tryngolza, which is priced at $595,000 per year per patient. Arrowhead aims to establish value in the SHTG market by initially targeting high-risk patients [6][7] - **Health Economics**: The cost of treating pancreatitis can exceed $60,000 per event, making Plozasiran's pricing compelling from both economic and human perspectives [8][9] Pipeline Developments - **New Candidates**: Arrowhead is developing a dual dimer targeting PCSK9 and ApoC3, which aims to lower LDL and remnant cholesterol [11][12] - **Obesity Programs**: Two programs, ARO-INHBE and ARO-ALK7, are in phase 1/2 studies, focusing on increasing lipolysis without affecting appetite [15][16] - **CNS Delivery**: ARO-MAPT targets tau tangles in Alzheimer's and tauopathies, with expectations for significant knockdown in cerebrospinal fluid (CSF) [22][24] Financial Position - **Cash Reserves**: Ended the fiscal year with $782 million, with additional capital from Sarepta and Novartis bringing total cash close to $1.2 billion [32] - **Funding Strategy**: The capital allows Arrowhead to advance core programs and aims for profitability by 2028, while reducing reliance on capital markets [32][33] Partnerships - **Sarepta Collaboration**: A significant partnership with Sarepta, valued at $800 million upfront and potential $10 billion in milestones, focuses on skeletal muscle programs [26][28] - **Novartis Partnership**: A $200 million upfront deal with Novartis for a preclinical Parkinson's disease drug, with potential for $2 billion in milestone payments [30][31] Conclusion - Arrowhead Pharmaceuticals is positioned for growth with a strong pipeline, strategic pricing, and significant partnerships, aiming to address critical health needs in cardiometabolic diseases and CNS disorders while maintaining a robust financial outlook.

Financial Data and Key Metrics Changes - The net loss for fiscal year 2025 was $2 million, a significant improvement from a net loss of approximately $599 million in fiscal year 2024, resulting in a loss of $0.01 per share compared to a loss of $5 per share [32] - Revenue for fiscal year 2025 totaled $829 million, driven primarily by licensing and collaboration agreements, with $697 million from Sarepta Therapeutics [32][33] - Total operating expenses increased to approximately $731 million in fiscal year 2025 from $605 million in fiscal 2024, primarily due to higher R&D and SG&A costs [35] Business Line Data and Key Metrics Changes - The FDA approval of Redemplo marked a major milestone, being the first FDA-approved siRNA medicine for familial chylomicronemia syndrome (FCS) [7][8] - Redemplo achieved an unprecedented reduction in triglycerides by approximately 80% from baseline as early as one month, with 50% of patients at the 25-mg dose achieving triglyceride levels below 500 mg per deciliter [24] - The company has made progress with Zodasiran, initiating the Yosemite phase III clinical trial for homozygous familial hypercholesterolemia (HoFH) [11][12] Market Data and Key Metrics Changes - There are an estimated 6,500 people in the U.S. living with genetic or clinical FCS, and approximately 750,000 patients with persistent chylomicronemia at high risk for acute pancreatitis [10][25] - The One Redemplo pricing model is set at $60,000 annually, aimed at providing consistent pricing across current and future indications [25] Company Strategy and Development Direction - The company is focusing on the cardiometabolic space, with ongoing development programs for Zodasiran and ArrowDiamond PA, targeting large populations without proper treatment options [14][15] - Arrowhead aims to have 20 individual drug candidates in clinical trials by the end of 2025, with a balanced pipeline of wholly owned and partnered programs [41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the commercial launch of Redemplo and the positive feedback received from healthcare professionals and patient societies [24][25] - The company anticipates that the commercial sales of Redemplo will not have a substantial impact on financial statements in fiscal year 2026, but believes its cash runway is sufficient to extend into fiscal year 2028 [39] Other Important Information - Arrowhead received a $200 million upfront payment from Novartis for a licensing agreement and is eligible for up to $2 billion in future milestone payments [18][37] - The company has expanded its clinical pipeline in CNS with AROMAPT, targeting tauopathies including Alzheimer's disease [15] Q&A Session Summary Question: Can you discuss the plan to show benefit in terms of acute pancreatitis for Plozasiran? - Management indicated that shots at three and four were powered for triglyceride reduction, with a reasonable chance to show a difference in acute pancreatitis, but emphasized that shots at five are specifically designed to demonstrate benefit in acute pancreatitis [45][46] Question: Can you provide more details on the upcoming data for obesity programs? - Management confirmed that initial data from the AROINHBE program will be shared in early January, with a focus on safety and biomarker data, while ARO-ALK7 will provide limited data focused on monotherapy safety [50][52] Question: What are the estimates on acute pancreatitis events accrual based on patient baseline characteristics? - Management noted that it is difficult to estimate the number of events due to the new criteria being used, but they expect to have a sufficient number of events based on the percentage of patients with a history of pancreatitis enrolled in the study [56] Question: Can you discuss the differentiation of the ArrowMapT program from J&J's failed anti-tau antibody? - Management highlighted that ArrowMapT targets intracellular tau, potentially reducing both intracellular and extracellular tau levels, unlike J&J's approach which primarily targets extracellular tau [62] Question: What is the visibility on launching a CBOT study? - Management indicated that they expect to have a clearer idea by summer regarding the data from ongoing studies, which will inform the timeline for launching pivotal studies [65]

Financial Data and Key Metrics Changes - The net loss for fiscal year 2025 was $2 million, a significant improvement from a net loss of approximately $599 million in fiscal year 2024, resulting in a loss of $0.01 per share compared to a loss of $5 per share [32] - Revenue for fiscal year 2025 totaled $829 million, driven primarily by licensing and collaboration agreements, with $697 million from Sarepta Therapeutics [32][33] - Total operating expenses for fiscal year 2025 were approximately $731 million, an increase from $605 million in fiscal 2024, primarily due to higher R&D and SG&A costs [33][34] - Cash and investments totaled $919 million as of September 30, 2025, up from $681 million a year earlier, reflecting strong cash flow from licensing agreements [35][36] Business Line Data and Key Metrics Changes - The FDA approved Redemplo, Arrowhead's first FDA-approved medicine, marking a major milestone as it transitions into the commercial stage [6][7] - Redemplo is indicated for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) and can be self-administered at home [19][20] - The One Redemplo pricing model is set at $60,000 annually, aimed at providing consistent pricing across indications [11][25] Market Data and Key Metrics Changes - There are an estimated 6,500 people in the U.S. living with genetic or clinical FCS, with a prescriber base comprising specialists such as lipidologists and endocrinologists [25] - The broader patient population at risk of acute pancreatitis includes approximately 750,000 patients with persistent chylomicronemia [10] Company Strategy and Development Direction - The company is focusing on the cardiometabolic space, with ongoing clinical trials for Zodasiran and ArrowDiamond PA, targeting conditions like homozygous familial hypercholesterolemia and atherosclerotic cardiovascular disease [12][13] - Arrowhead aims to have 20 individual drug candidates in clinical trials by the end of 2025, with a balanced pipeline of wholly owned and partnered programs [39] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the commercial launch of Redemplo and the encouraging feedback from the FCS community [39] - The company does not anticipate substantial financial impact from Redemplo sales in fiscal year 2026 but believes its cash runway is sufficient to support operations into fiscal year 2028 [38] Other Important Information - Arrowhead received a $200 million upfront payment from Novartis for a licensing agreement and is eligible for up to $2 billion in future milestone payments [36][37] - The company has made significant progress in business development, including a $200 million milestone payment from Sarepta for ARO-DM1 [17][38] Q&A Session Summary Question: What is the plan to show benefit in terms of acute pancreatitis for Plozasiran? - Management indicated that while shots at three and four were powered for triglyceride reduction, there is reasonable power to see a difference in acute pancreatitis, with a specific design for SHASTA-5 to demonstrate benefit [42][44][45] Question: Can you provide details on the upcoming data for obesity programs? - Management confirmed that initial data from the ARO-INHBE program will be shared in early January, with a focus on safety and biomarker data [48][50] Question: What are the estimates on acute pancreatitis events accrual based on patient baseline characteristics? - Management noted that it is challenging to predict due to the adoption of modified Atlanta criteria for adjudication, but they expect a sufficient number of events based on patient history [53][54] Question: Can you discuss the differentiation of ArrowMapT from J&J's failed anti-tau antibody? - Management highlighted that ArrowMapT targets intracellular tau, potentially reducing both intracellular and extracellular tau levels, unlike J&J's approach [57][59] Question: What is the visibility on launching a CBOT study? - Management stated that they expect to have a clearer idea by summer 2026 based on data from ongoing studies, with plans to move into pivotal studies if results are favorable [62][63]